医学
曲妥珠单抗
拉帕蒂尼
西妥昔单抗
肿瘤科
癌症
内科学
化疗
靶向治疗
不利影响
乳腺癌
结直肠癌
作者
Jan Kulig,Piotr Kołodziejczyk,Piotr Kulig,J Legutko
标识
DOI:10.1177/1078155212449030
摘要
In patients with metastatic gastric cancer, median overall survival remains under 1 year and standard chemotherapy regimens are not able to substantially improve the prognosis of the patients. Amplification and over-expression of HER2 is reported in approximately 20% of gastric tumours, challenging the use of targeted therapies. There are several targeted therapies in different stages of clinical development with trastuzumab being the first overcoming the regulatory hurdle and getting European Medicines Agency approval. In patients with advanced gastric or gastro-oesophageal junction cancer, addition of trastuzumab to chemotherapy significantly improved overall survival compared with chemotherapy alone. Addition of trastuzumab to chemotherapy did not increase the incidence of adverse events. Other agents targeting the HER2 pathway (lapatinib) or other domains of epidermal growth factor receptor family (cetuximab) are currently being investigated for the treatment of an advanced gastric cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI